BioAmber (Plymouth, MN) a commercial-stage biofuel company focused on the production bio-succinic acid and other bio-based chemicals, closed a $30M Series C financing. Participants include Naxos Capital, Sofinnova Partners, Mitsui & Co. and the Cliffton Group.

Creabilis (Luxembourg) a clinical-stage biotechnology company focused dermatology and inflammatory diseases, closed a $20M Series B financing. Participants include Abbott Biotech Ventures, Neomed and Sofinnova Partners.

Hookipa Biotech (Austria) a development-stage pharmaceutical company focused on prophylactic and therapeutic vaccines for viral diseases, closed $9.7M Series A financing. Participants include Sofinnova Partners and Forbion Capital Partners.

NuCana BioMed (United Kingdom) a preclinical-stage pharmaceutical company focused oncology, closed a $10.4M Series A financing. Participants include Sofinnova Partners, Morningside Ventures, Scottish Venture Fund and Alida Capital International.

Avantium (Netherlands) a commercial-stage clinical research organization focused on high-throughput R&D, closed a $36.2M Series B financing. Participants include Sofinnova Partners, Aster Capital, De Hoge Dennen, Aescap Venture, Capricorn Cleantech Fund, ING Corporate Investments and Navitas Capital. The 2Q11 OnBioVC Trend Analysis will be published on Tue 6 September. Advertising opportunities are still available. Reach [...]

DBV Technologies (France) a clinical-stage drug:device biopharma company focused on non invasive immunotherapy delivery for food allergies, closed a $25.5M Series C financing. Participants include InnoBio Fund, Lundbeckfond Ventures, ALTO Invest, Sofinnova Partners, ALK Abello and Apax Partners.

Noxxon Pharma (Germany) a clinical-stage biopharmaceutical company focused on the development of aptamers for the treatment of inflammation and hematological indications closed a $2.6M Series D financing, bringing the total round to $42.6M. Participants include NGN Capital, TVM Capital, Sofinnova Partners, Edmond de Rothschild Investment Partners, Seventure Partners, VC Fonds Technologie Berlin, Dow Venture Capital, [...]

Cerenis Therapeutics (France), a clinical-stage biopharmaceutical company focused on the regression of atherosclerotic plaque and the enhancement of HDL function, closed a $40M Series C financing. Participants include Fund for Strategic Investment, Sofinnova Partners, HealthCap, Alta Partners, TVM Capital, EDF Ventures, OrbiMed and DAIWA Corporate Investment.

Noxxon Pharma (Germany) a clinical-stage biopharmaceutical company focused on the development of aptamers for the treatment of inflammation and hematological indications closed a $40M Series D financing. Participants include NGN Capital, TVM Capital, Sofinnova Partners, Edmond de Rothschild Investment Partners, Seventure Partners, VC Fonds Technologie Berlin, Dow Venture Capital, Fcp Medical BioHealth-Trends, IBG Beteiligungsgesellschaft Sachsen-Anhalt [...]

Omthera Pharmaceuticals (Bedminster, NJ) a clinical-stage specialty biopharma company focused on an Omega-3 fatty acid containing DHA and EPA as a therapy for dyslipidemia, closed a $6.5M Series A financing. Participants include Sofinnova Partners.

Crescendo Biologics (United Kingdom) a development-stage biopharma focused on a fragment antibody technology platforms, closed a $7.3M Series A financing. Participants include Sofinnova Partners, Aitua, Avlar BioVentures and Rainbow Seed Fund. Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb.